Drug intelligence / Profile preview

insulin lispro + insulin lispro protamine

Development stage
Approved
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Insulin lispro + insulin lispro protamine is a fixed-ratio combination of two human insulin analogs used to improve glycemic control in adults with diabetes mellitus (type 1 and type 2). Insulin lispro is a rapid-acting insulin analog that quickly lowers blood glucose after injection. Insulin lispro protamine is an intermediate-acting form created by complexing the rapid-acting analog with protamine to slow its absorption and prolong its effect. The combination provides both prandial (mealtime) and basal (background) glucose control in a single injection. It typically starts working within 10–20 minutes after subcutaneous administration, peaks at about two hours, and has effects lasting up to approximately 22–24 hours[1][3][6]. The product is available in different ratios (e.g., "Mix75/25" contains 75% intermediate-acting [lispro protamine] and 25% rapid-acting [lispro]; "Mix50/50" contains equal parts of each)[6]. Developed by Eli Lilly[6], it should be administered shortly before meals.

Brand names
HumaLOG Mix 75/25HumaLOG Mix 75/25 KwikPenHumaLOG Mix 50/50HumaLOG Mix 50/50 KwikPenHumaLOG Mix 75/25 PenHumaLOG Mix 50/50 PenInsulin Lispro Protamine-Insulin Lispro Mix75/25 KwikPen
Other names
insulin lispro and insulin lispro protamine
02

Targets

INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on insulin lispro + insulin lispro protamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro + insulin lispro protamine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call